Want to see BSEM full AI Analyst Report?
EarningsQ2 2026 Earnings Report
BSEM Q2 2026 EPS Results
Actual EPS-$0.52
Consensus EPS-$0.50
Beat/MissMissed by -$0.02
One Year Ago EPS-$0.03
BSEM Q2 2026 Revenue Results
Actual Revenue$7.90M
Expected Revenue$6.35M
Beat/MissBeat by +$1.55M
YoY Revenue Growth-83.98%
Earnings Announcement Details
QuarterQ2 2026
Date08/12/2026
TimeAfter Close
Conference CallWednesday, August 12, 2026
BSEM Upcoming Earnings
BioStem Technologies's next earnings date is estimated for November 17, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
BSEM Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Neutral
The call highlights strong operating execution around integration, commercial expansion, product and IP progress, sequential revenue growth (+29.5% quarter-over-quarter) and a raised revenue outlook. However, meaningful near-term financial challenges were emphasized: a $9.0 million GAAP loss, adjusted EBITDA loss, cash down to $7.0 million (≈49% decline sequentially), a $10 million contingent payment pending, and anticipated H2 margin pressure tied to legacy inventory. Management is progressing on strategic initiatives (Nasdaq uplisting, CRM/ERP integration, salesforce scale, patents, clinical data and a planned manufacturing transfer), but near-term liquidity and profitability depend on executing financing plans and the 2027 manufacturing transfer. Overall, positive operational momentum is balanced by significant near-term financial and execution risks.Company Guidance
Sequential Revenue Growth
Total revenue of $7.9 million in Q2 2026, up from $6.1 million in Q1 2026, a sequential increase of $1.8 million (+29.5%).
Hospital Revenue Ramp
Hospital revenue of $6.7 million in Q2 2026 versus $5.4 million in Q1 2026, an increase of $1.3 million (+24.1%), supporting the company's shift to a hospital-focused model.
Physician Office Improvement
Physician office revenue rose to $1.1 million from $772,000 in Q1 2026, a sequential increase of $328,000 (+42.5%), though management expects only gradual recovery.
Gross Profit and Stable Margin
Gross profit increased to $4.8 million (from $3.8 million in Q1) — a +$1.0 million change (+26.3%) — with gross margin holding steady at 61% sequentially.
Nasdaq Uplisting
Completed uplisting to the Nasdaq Capital Market (common stock began trading on August 7, 2026), broadening visibility and access to capital.
Commercial and Operational Integration Progress
Completed transition of sales logistics, invoicing, and collections in-house; launched integrated CRM with ERP to automate order processing and improve visibility into account activity and utilization.
Salesforce Expansion
Commercial organization expanded and on track to exceed 40 W2 representatives and >30 independent agents by year-end; currently 30 direct reps plus 5 regional directors, more than doubling direct sales since acquisition.
Clinical and IP Momentum
Expect first 510(k) cleared product later in 2026; VLU randomized trial top-line data expected late 2026; DFU top-line results published in late 2025. Also received eight new U.S. design patents for fenestrated human placental allograft designs.
Raised Full-Year Revenue Guidance
Updated full-year 2026 revenue guidance to $26 million–$29 million, up from prior $25 million–$29 million (lower bound increased by $1 million).
Manufacturing Transfer Opportunity
Plan to transfer Neox and Clarix manufacturing in H1 2027 with minimal capex; management expects improved operating leverage and gross margin uplift post-transfer and estimates potential margin improvement on the order of ~15–20 percentage points (targeting into the 70s).
BSEM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed